Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Transplantation of hematopoietic cells from a donor with a single matched HLA haplotype, combined with post-transplant cyclophosphamide, may be a good alternative when…
NEW YORK (Reuters Health) – Patients with follicular non-Hodgkin lymphoma that has transformed into aggressive-histology lymphoma do better when treated with high-dose chemotherapy followed by autologous stem-cell transplantation…
NEW YORK (Reuters Health) – Reducing exposure to alkylating agents in patients with Hodgkin lymphoma is key to reducing the risk of developing therapy-related acute myeloid leukemia or…
NEW YORK (Reuters Health) – Agents that target the mTOR axis, which have become particularly important in the treatment of advanced renal cell carcinoma (RCC), have significant adverse…
NEW YORK (Reuters Health) – Revised guidelines on the assessment and management of reproductive complications in young female cancer survivors provide the latest evidence-based recommendations for evaluation and…
NEW YORK (Reuters Health) – Symptomatic lymphoceles that develop after retroperitoneal lymph node dissection in gynecologic cancer patients can be dealt with safely and effectively by laparoscopic lymphocele…
NEW YORK (Reuters Health) – While the risk of prostate cancer appears to be reduced in men taking dutasteride, there are indications that cancer may emerge once the…
NEW YORK (Reuters Health) – TNFerade biologic, a novel method of delivering tumor necrosis factor to tumor cells by gene transfer, does not prolong survival when added to…
NEW YORK (Reuters Health) – Patients with non-castrate metastatic prostate cancer receiving androgen deprivation therapy fare no better with the addition of docetaxel chemotherapy, a French and Belgian…
Hanne Mintz, co-chair of the Meso Foundation Board of Directors, discusses the foundation’s goals to find effective treatment and ultimately a cure for mesothelioma. She recommends both physicians…
